MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-14-2025
ADiTx Therapeutics Operating Expenses 2011-2026 | ADTX
Annual Operating Expenses ADiTx Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.4 M | 26 M | 25.6 M | 42 M | 8.87 M | 5.87 M | 5.61 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42 M | 5.61 M | 20.2 M |
Quarterly Operating Expenses ADiTx Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.15 M | 5.61 M | - | 4.24 M | 6 M | 11.5 M | - | 8.11 M | 4.27 M | 5.82 M | - | 5.48 M | 5.81 M | 6.14 M | - | 6.07 M | 5.78 M | 6.09 M | - | 2.74 M | 398 K | 1.06 M | - | 1.08 M | 2.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.5 M | 398 K | 5 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.55 | -2.18 % | $ 1.06 B |  Canada |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
101 M | $ 15.66 | -5.32 % | $ 3.73 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 20.16 | 1.51 % | $ 2.54 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
127 M | $ 75.5 | -1.35 % | $ 1.46 B | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.48 | -9.2 % | $ 378 M | Britain |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 34.35 | -3.75 % | $ 3.57 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
45.1 M | $ 7.8 | -7.36 % | $ 33.8 M | USA |
 |
CorMedix
CRMD
|
49 M | $ 6.32 | -11.24 % | $ 322 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
Champions Oncology
CSBR
|
12.5 M | $ 5.79 | -3.58 % | $ 79.1 M | USA |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 160.44 | -2.22 % | $ 7.98 B | USA |
 |
BridgeBio Pharma
BBIO
|
304 M | $ 65.38 | -1.74 % | $ 12.5 B | USA |
 |
Denali Therapeutics
DNLI
|
502 M | $ 19.69 | -3.34 % | $ 3.24 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Edesa Biotech
EDSA
|
6.71 M | $ 3.8 | -10.9 % | $ 12.2 M | USA |
 |
Equillium
EQ
|
50.6 M | $ 1.79 | 2.0 % | $ 62.2 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.75 | -2.14 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 60.47 | 0.07 % | $ 11.6 B | USA |
 |
Eton Pharmaceuticals
ETON
|
22.3 M | $ 17.04 | -2.77 % | $ 437 M | USA |